References
- ACHEAMPONG, A. A., CHIEN, D.-S., LAN', S., VEKICH, S., BREAU, A., USANSKY, J., HARCOURT, D., MUNK, S. A., NGUYEN, H., GARST, M. and TANG-Liu, D., 1996, Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica, 26, 1035–1055.
- BEAMAND, J. A., PRICE, R. J., CUNNINGHAME, M. E. and LAKE, B. G., 1993, Culture of precision-cut liver slices: effect of some peroxisome proliferators. Food and Chemical Toxicology, 31, 137–147.
- BEEDHAM, C., 1987, Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. In G. P. Ellis and G. B. West (eds), Progress in Medicinal Chemistry, vol. 24 (Amsterdam: Elsevier), pp. 85–127.
- BEEDHAM, C., BRUCE, S. E., CRITCHLEY, D. J., AL-TAvis, Y. and RANCE, D. J., 1987, Species variation in hepatic aldehyde oxidase activity. European Journal of Drug Metabolism and Pharmacokine tics, 12, 307–310.
- BEER, B., IENI, J. R., Wu, W.-H., CLODY, D., AMORUSI, P., ROSE, J., MANT, T., GAUDREAULT, J., CATO, A. and STERN, W., 1994, A placebo-controlled evaluation of single, escalating doses of CL-284,846, a non-benzodiazepine hypnotic. Journal of Clinical Pharmacology, 34, 335–344.
- CHAUDHARY, I., DEMALO, W. and KANTROWITZ, J., 1994, Species comparison of in vitro and in vivo metabolism of CL-284,846, a non-benzodiazepine sedative/hypnotic agent. Pharmaceutical Research, 11, S391.
- DIXON, M., 1953, The determination of enzyme inhibitor constants. Biochemical Journal, 55, 170–171.
- JOHNS, D. G., 1967, Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. Journal of Clinical Investigation, 46, 1492–1505.
- JOHNSON, C., STUBLEY-BEEDHAM, C. and STELL, J. G. P., 1984, Elevation of molybdenum hydroxylase levels in rabbit liver after ingestion of phthalazine or its hydroxylated metabolite. Biochemical Pharmacology, 33, 3699–3705.
- JOHNSON, C., STUBBLEY-BEEDHAM, C. and STELL, J. G. P., 1985, Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochemical Pharmacology, 34, 4251–4256.
- KAWASHIMA, K., Hosoi, K., NARUKE, T., SHIBA, T., KITAMURA, M. and WATABE, T., 1999, Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metabolism and Disposition, 27, 422–428.
- LAKE, B. G., BALL, S. E., RENWICK, A. B., TREDGER, J. M., KAO, J., BEAMAND, J. A. and PRICE, R. J., 1997, Induction of CYP3A isoforms in cultured precision-cut human liver slices. Xenobiotica, 27, 1165–1173.
- LAKE, B. G., TREDGER, J. M., RENWICK, A. B., BARTON, P. B. and PRICE, R. J., 1998, 3,3'-Diindolylmethane induces CYP1A2 in cultured precision-cut human liver slices. Xenobiotica, 28, 803–811.
- LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RkNDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
- RAJAGOPALAN, K. V. and HANDLER, P., 1966, Aldehyde oxidase. Methods in Enzymology, 9, 364-368. RASHIDI, M. R., SMITH, J. A., CLARKE, S. E. and BEEDHAM, C., 1995, Inhibition of human and guinea-pig liver aldehyde oxidases in-vitro. Journal of Pharmacy and Pharmacology, 47, 1090.
- RASHIDI, M. R., SMITH, J. A., CLARKE, S. E. and BEEDHAM, C., 1997, In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metabolism and Disposition, 25, 805–813.
- RENWICK, A. B., MISTRY, H., BALL, S. E., WALTERS, D. G., Kao, J. and LAKE, B. G., 1998, Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 28, 337–348.
- RODRIGUES, A. D., 1994, Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochemical Pharmacology, 48, 197–200.
- RODRIGUES, A. D., FERRERO, J. L., AMANN, M. T., ROTERT, G. A., CEPA, S. P., SURBER, B. W., MACHINIST, J. M., TICH, N. R., SULLIVAN, J. P., GARVEY, D. S., FITZGERALD, M. and ARNERIC, S. P., 1994, The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, Cynomolgus monkeys, and humans. Drug Metabolism and Disposition, 22, 788–798.
- ROSEN, A. S., FOURNIE, P., DARWISH, M., DANJOU, P. and TROY, S. M., 1999, Zaleplon pharmacokinetics and absolute bioavailability. Biopharmaceutics and Drug Disposition, 20, 171–175.
- SOMOGYI, A. and MUIRHEAD, M., 1987, Pharmacokinetic interactions of cirnetidine 1987. Clinical Pharmacokinetics, 12, 321–366.
- STEENSMA, A., BEAMAND, J. A., WALTERS, D. G., PRICE, R. J. and LAKE, B. G., 1994, Metabolism of coumarin and 7-ethoxycoumarin by rat, guinea pig, Cynomolgus monkey and human precision-cut liver slices. Xenobiotica, 24, 893–907.
- TANAKA, E., 1998, Clinically important pharmacokinetic drug—drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23, 403–416.
- WU, W. H., DICIOCCIO, A. T., DEMAIO, W., AMORUSI, P., TONELLI, A. P. and MAYER, P. R., 1996, Mass balance and pharmacokinetics of zaleplon, a non-benzodiazepine sedative/hypnotic, in man. Pharmaceutical Research, 13, S487.
- YOSHIHARA, S. and TATSUMI, K., 1986, Kinetic and inhibition studies on reduction of diphenyl sulphoxide by guinea pig liver aldehyde oxidase. Archives of Biochemistry and Biophysics, 249, 8–14.